Search for Clinical Trial Results

Sponsored By

Keratoconjunctivitis Sicca - 24 Studies Found

Status Study
Completed Study Name: Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2013-03-21
Interventions:
  • Drug: Lotemax Gel + Restasis O
Completed Study Name: Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2006-07-06
Interventions:
  • Drug: CF101 Orally CF101 1mg
Completed Study Name: Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2016-02-13
Interventions:
  • Drug: cyclosporine Other Name:
Completed Study Name: Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2005-08-05
Interventions: Drug: Pimecrolimus
Completed Study Name: Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
Condition: Keratoconjunctivitis Sicca
Date: 2009-04-17
Interventions:
  • Dietary Supplement: Hydroeye 2
Completed Study Name: Study of Rebamipide Eye Drops to Treat Dry Eye
Condition: Keratoconjunctivitis Sicca
Date: 2005-09-12
Interventions: Drug: Rebamipide
Enrolling by invitation Study Name: An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2016-07-24
Interventions: Drug: OTX-101 0.09% 0.09% cyclosporine nanomicellar solution
Completed Study Name: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Date: 2013-07-11
Interventions:
  • Drug: R348 Ophthalmic Solution, 0.2%

Terminated Study Name: Omega-3 Fatty Acid Supplements and Dry Eye
Condition: Keratoconjunctivitis Sicca
Date: 2010-09-30
Interventions:
  • Dietary Supplement: Omega-3 Fatty Acid

Completed Study Name: A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Condition: Keratoconjunctivitis Sicca
Date: 2009-02-24
Interventions: Drug: voclosporin ophthalmic solution 0.02%, 0.2% t.i.d. or b.i.d.
Next >>>